Creating a new generation of small molecule serine protease inhibitors

News

KalVista Pharmaceuticals to Support Global Conference Focused on Hereditary Angioedema

19 May 2016 Read more...

KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in DME and HAE

22 July 2015 Read more...

Registered Office: Building 227, Tetricus Science Park, Porton Down, SP4 0JQ, United Kingdom Registered in England. Registered No: 07543947